Bottles of a trial Covid-19 vaccine on a table in a lab in Brussels on June 18, 2020. (Photo: Vincent Kalut/Photonews via Getty Images)
Sep 17, 2020
Oxfam on Thursday reiterated its call for a "people's vaccine" as the anti-poverty group released a new analysis showing that a handful of rich nations representing just 13 percent of the world's population have snatched up over half of the promised Covid-19 vaccine doses.
"Access to a life-saving vaccine shouldn't depend on where you live or how much money you have," Robert Silverman, advocacy manager in Oxfam America's Private Sector department, said in a statement.
"The development and approval of a safe and effective vaccine is crucial," he said, "but equally important is making sure the vaccines are available and affordable to everyone."
\u201cUPDATE: A small group of rich nations - representing just 13% of world population - have bought up MORE THAN HALF the supply of leading #COVID19 vaccine contenders.\n\nTime for a #PeoplesVaccine - free for everyone, everywhere.\n\n\ud83d\udc49\ud83c\udffe https://t.co/rEBmLdd7h9\u201d— Oxfam International (@Oxfam International) 1600302600
In its findings, based on data from science analytics company Airfinity, Oxfam notes that nine vaccines are currently going through phase 3 clinical trials. Supply deals are known for five of those potential vaccines, and are being developed pharmaceutical giants by AstraZeneca, Gamaleya/Sputnik, Moderna, Pfizer and Sinovac.
The analysis comes amid swelling calls from global leaders, health experts, and groups including Oxfam for a so-called people's vaccine for the novel coronavirus. That effort would put the needs of public health above corporate profits and reject nationalist approaches towards vaccine acquisition.
According to Oxfam, out of supply deals inked for 5.3 billion doses, 51 percent--2.728 billion--were bought by wealthy nations including the U.K., U.S., Australia, Hong Kong and Macau, Japan, Switzerland, and Israel, and well as the European Union.
The group further warns that even if the five potential vaccines turn out to be sufficiently safe and effective--an unlikely scenario--the coming year would still be marked by the public health crisis because 61% of the world's population would likely not have a vaccine until at least 2022.
As Silverman noted in his statement, "Covid-19 anywhere is Covid-19 everywhere."
That simply underscores the need for a people's vaccine, says Chema Vera, interim executive director of Oxfam International.
"Governments will prolong this crisis in all of its human tragedy and economic damage if they allow pharmaceutical companies to protect their monopolies and profits," said Vera.
"No single corporation will ever be able to meet the world's need for a ovid-19 vaccine," he said, urging companies to "share their knowledge free of patents and to get behind a quantum leap in production to keep everyone safe."
"We need a people's vaccine, not a profit vaccine," Vera said.
An Unconstitutional Rampage
Trump and Musk are on an unconstitutional rampage, aiming for virtually every corner of the federal government. These two right-wing billionaires are targeting nurses, scientists, teachers, daycare providers, judges, veterans, air traffic controllers, and nuclear safety inspectors. No one is safe. The food stamps program, Social Security, Medicare, and Medicaid are next. It’s an unprecedented disaster and a five-alarm fire, but there will be a reckoning. The people did not vote for this. The American people do not want this dystopian hellscape that hides behind claims of “efficiency.” Still, in reality, it is all a giveaway to corporate interests and the libertarian dreams of far-right oligarchs like Musk. Common Dreams is playing a vital role by reporting day and night on this orgy of corruption and greed, as well as what everyday people can do to organize and fight back. As a people-powered nonprofit news outlet, we cover issues the corporate media never will, but we can only continue with our readers’ support. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Oxfam on Thursday reiterated its call for a "people's vaccine" as the anti-poverty group released a new analysis showing that a handful of rich nations representing just 13 percent of the world's population have snatched up over half of the promised Covid-19 vaccine doses.
"Access to a life-saving vaccine shouldn't depend on where you live or how much money you have," Robert Silverman, advocacy manager in Oxfam America's Private Sector department, said in a statement.
"The development and approval of a safe and effective vaccine is crucial," he said, "but equally important is making sure the vaccines are available and affordable to everyone."
\u201cUPDATE: A small group of rich nations - representing just 13% of world population - have bought up MORE THAN HALF the supply of leading #COVID19 vaccine contenders.\n\nTime for a #PeoplesVaccine - free for everyone, everywhere.\n\n\ud83d\udc49\ud83c\udffe https://t.co/rEBmLdd7h9\u201d— Oxfam International (@Oxfam International) 1600302600
In its findings, based on data from science analytics company Airfinity, Oxfam notes that nine vaccines are currently going through phase 3 clinical trials. Supply deals are known for five of those potential vaccines, and are being developed pharmaceutical giants by AstraZeneca, Gamaleya/Sputnik, Moderna, Pfizer and Sinovac.
The analysis comes amid swelling calls from global leaders, health experts, and groups including Oxfam for a so-called people's vaccine for the novel coronavirus. That effort would put the needs of public health above corporate profits and reject nationalist approaches towards vaccine acquisition.
According to Oxfam, out of supply deals inked for 5.3 billion doses, 51 percent--2.728 billion--were bought by wealthy nations including the U.K., U.S., Australia, Hong Kong and Macau, Japan, Switzerland, and Israel, and well as the European Union.
The group further warns that even if the five potential vaccines turn out to be sufficiently safe and effective--an unlikely scenario--the coming year would still be marked by the public health crisis because 61% of the world's population would likely not have a vaccine until at least 2022.
As Silverman noted in his statement, "Covid-19 anywhere is Covid-19 everywhere."
That simply underscores the need for a people's vaccine, says Chema Vera, interim executive director of Oxfam International.
"Governments will prolong this crisis in all of its human tragedy and economic damage if they allow pharmaceutical companies to protect their monopolies and profits," said Vera.
"No single corporation will ever be able to meet the world's need for a ovid-19 vaccine," he said, urging companies to "share their knowledge free of patents and to get behind a quantum leap in production to keep everyone safe."
"We need a people's vaccine, not a profit vaccine," Vera said.
Oxfam on Thursday reiterated its call for a "people's vaccine" as the anti-poverty group released a new analysis showing that a handful of rich nations representing just 13 percent of the world's population have snatched up over half of the promised Covid-19 vaccine doses.
"Access to a life-saving vaccine shouldn't depend on where you live or how much money you have," Robert Silverman, advocacy manager in Oxfam America's Private Sector department, said in a statement.
"The development and approval of a safe and effective vaccine is crucial," he said, "but equally important is making sure the vaccines are available and affordable to everyone."
\u201cUPDATE: A small group of rich nations - representing just 13% of world population - have bought up MORE THAN HALF the supply of leading #COVID19 vaccine contenders.\n\nTime for a #PeoplesVaccine - free for everyone, everywhere.\n\n\ud83d\udc49\ud83c\udffe https://t.co/rEBmLdd7h9\u201d— Oxfam International (@Oxfam International) 1600302600
In its findings, based on data from science analytics company Airfinity, Oxfam notes that nine vaccines are currently going through phase 3 clinical trials. Supply deals are known for five of those potential vaccines, and are being developed pharmaceutical giants by AstraZeneca, Gamaleya/Sputnik, Moderna, Pfizer and Sinovac.
The analysis comes amid swelling calls from global leaders, health experts, and groups including Oxfam for a so-called people's vaccine for the novel coronavirus. That effort would put the needs of public health above corporate profits and reject nationalist approaches towards vaccine acquisition.
According to Oxfam, out of supply deals inked for 5.3 billion doses, 51 percent--2.728 billion--were bought by wealthy nations including the U.K., U.S., Australia, Hong Kong and Macau, Japan, Switzerland, and Israel, and well as the European Union.
The group further warns that even if the five potential vaccines turn out to be sufficiently safe and effective--an unlikely scenario--the coming year would still be marked by the public health crisis because 61% of the world's population would likely not have a vaccine until at least 2022.
As Silverman noted in his statement, "Covid-19 anywhere is Covid-19 everywhere."
That simply underscores the need for a people's vaccine, says Chema Vera, interim executive director of Oxfam International.
"Governments will prolong this crisis in all of its human tragedy and economic damage if they allow pharmaceutical companies to protect their monopolies and profits," said Vera.
"No single corporation will ever be able to meet the world's need for a ovid-19 vaccine," he said, urging companies to "share their knowledge free of patents and to get behind a quantum leap in production to keep everyone safe."
"We need a people's vaccine, not a profit vaccine," Vera said.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.